Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PAN3 antisense RNA 1 (PAN3-AS1)
- Target
- PAN3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding transcript
01
Overview
PAN3 antisense RNA 1 (PAN3-AS1) is a long non-coding RNA gene transcribed antisense to the PAN3 gene on the human genome[3][5]. Like other antisense RNAs, it may regulate the expression of its sense partner gene by mechanisms such as transcriptional interference, chromatin remodeling, or direct RNA-RNA interactions[4]. The biological function and disease relevance of PAN3-AS1 specifically are largely uncharacterized, but the broader class of antisense lncRNAs to which it belongs is increasingly recognized as important in transcriptional regulation and involved in pathological processes such as cancer, epigenetic silencing, and imprinting[4]. No drugs or biomarkers currently target PAN3-AS1; its potential as a therapeutic or diagnostic molecule has not yet been demonstrated.
02
Mechanism of action
not applicable; no drugs currently target this lncRNA
03
Biological functions
Regulation of gene expression (through antisense interaction with PAN3 and potentially other genes)Post-transcriptional regulation (may influence mRNA stability, translation, or splicing as observed for other antisense RNAs)
04
Disease associations
Potential implication in cancer or disease processes, as other antisense lncRNAs are often dysregulated in cancer and can influence tumorigenesis
05
Safety considerations
not established; as an endogenous lncRNA, safety concerns would be theoretical and related to lncRNA-targeted approaches in general (for example, off-target effects of antisense oligonucleotide therapies), not specific to PAN3-AS1
Beyond the preview
Go deeper on PAN3 antisense RNA 1 (PAN3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAN3 antisense RNA 1 (PAN3-AS1).